Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02478190 · ClinicalTrials.gov registry record · NA
ED Management of Severe Hyperglycemia: A Clinical Trial
A NA study, sponsored by Hennepin Healthcare Research Institute.
- Completed
- Registry status
- NA
- Development phase
- 110
- Enrollment target
NCT02478190: Completed NA study, sponsored by Hennepin Healthcare Research Institute.
NCT02478190 is a NA study that has completed, run by Hennepin Healthcare Research Institute. The registered enrollment target is 110 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02478190, a NA study, has completed, sponsored by Hennepin Healthcare Research Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 110 participants
- Enrollment target
Study Summary
Emergency Department (ED) patients with severe hyperglycemia will be randomized to two treatment goals: discharge glucose less than 600 mg/dL or less than 350 mg/dL. Randomization is stratified by whether the chief complaint is "High Blood Sugar" in the electronic medical record or other.
Primary Outcome
Time elapsed from when the patient is roomed until the time the MD places discharge order, by review of the Electronic Medical record by a blinded abstractor.
Interventions
- OTHER Tight control: goal glucose 350 mg/dL or lower
- OTHER Loose control: goal glucose 600 mg/dL or lower
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2015-06 |
| Est. Completion | 2017-12 |
| Phase | NA |
What the finished NCT02478190 record still lists
NCT02478190 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 2 interventions - of which Tight control: goal glucose 350 mg/dL or lower is the first listed.
NCT02478190 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02478190 about?
NCT02478190 is a clinical study titled "ED Management of Severe Hyperglycemia: A Clinical Trial". Emergency Department (ED) patients with severe hyperglycemia will be randomized to two treatment goals: discharge glucose less than 600 mg/dL or less than 350 mg/dL. Randomization is stratified by whether the chief complaint is "High Blood Sugar" in the electronic medical record or other.
What is the current status of trial NCT02478190?
This trial is currently completed. It is a NA study. The enrollment target is 110 participants. The study started on 2015-06. Estimated completion is 2017-12.
What interventions are being tested in trial NCT02478190?
The interventions under investigation include: Tight control: goal glucose 350 mg/dL or lower (OTHER), Loose control: goal glucose 600 mg/dL or lower (OTHER).
Who is sponsoring clinical trial NCT02478190?
This trial is sponsored by Hennepin Healthcare Research Institute, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02478190's enrollment target sits among peer trials
110 816th of 2000 higher than 1,176 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia